1
|
Jeon B, Lee YJ, Shin J, Choi MJ, Lee CE, Son MK, Park JH, Kim BS, Kim HR, Jung KH, Cha JH, Hong SS. A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc/Bcl-2/Mcl-1 triple targeting. Am J Cancer Res 2023; 13:452-463. [PMID: 36895970 PMCID: PMC9989607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Accepted: 01/12/2023] [Indexed: 03/11/2023] Open
Abstract
Double hit diffuse large B-cell lymphoma (DLBCL) with rearrangement and overexpression of both c-Myc and Bcl-2 responds poorly to standard R-CHOP therapy. In a recent phase I study, Venetoclax (ABT-199) targeting Bcl-2 also exhibited disappointing response rates in patients with relapsed/refractory DLBCL, suggesting that targeting only Bcl-2 is not sufficient for achieving successful efficacy due to the concurrent oncogenic function of c-Myc expression and drug resistance following an increase in Mcl-1. Therefore, co-targeting c-Myc and Mcl-1 could be a key combinatorial strategy to enhance the efficacy of Venetoclax. In this study, BR101801 a novel drug for DLBCL, effectively inhibited DLBCL cell growth/proliferation, induced cell cycle arrest, and markedly inhibited G0/G1 arrest. The apoptotic effect of BR101801 was also observed by increased Cytochrome C, cleaved PARP, and Annexin V-positive cell populations. This anti-cancer effect of BR101801 was confirmed in animal models, where it effectively inhibited tumor growth by reducing the expression of both c-Myc and Mcl-1. Furthermore, BR101801 exhibited a significant synergistic antitumor effect even in late xenograft models when combined with Venetoclax. Our data strongly suggest that c-Myc/Bcl-2/Mcl-1 triple targeting through a combination of BR101801 and Venetoclax could be a potential clinical option for double-hit DLBCL.
Collapse
Affiliation(s)
- Byeongwook Jeon
- Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences & Engineering, Inha University 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Korea.,Boryung Pharmaceutical 107 Neungan-ro, Danwon-gu, Ansan-si 15425, Gyeonggi-do, Korea
| | - Yun Ji Lee
- Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences & Engineering, Inha University 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Korea
| | - Jisoo Shin
- Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences & Engineering, Inha University 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Korea
| | - Min-Ji Choi
- Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences & Engineering, Inha University 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Korea
| | - Chae-Eun Lee
- Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences & Engineering, Inha University 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Korea
| | - Mi Kwon Son
- Boryung Pharmaceutical 107 Neungan-ro, Danwon-gu, Ansan-si 15425, Gyeonggi-do, Korea
| | - Jung Hee Park
- Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences & Engineering, Inha University 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Korea
| | - Bong-Seog Kim
- Boryung Pharmaceutical 107 Neungan-ro, Danwon-gu, Ansan-si 15425, Gyeonggi-do, Korea
| | - Hong Ro Kim
- Boryung Pharmaceutical 107 Neungan-ro, Danwon-gu, Ansan-si 15425, Gyeonggi-do, Korea
| | - Kyung Hee Jung
- Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences & Engineering, Inha University 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Korea
| | - Jong-Ho Cha
- Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences & Engineering, Inha University 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Korea
| | - Soon-Sun Hong
- Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences & Engineering, Inha University 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Korea
| |
Collapse
|